blog

Why Blood NAD Measurements May Signal Cardiovascular Problems Rather Than Normal Aging

A human study found no age-related drop in healthy adults’ whole-blood NAD. Its cardiovascular links raise research questions, not a validated test.

Why Blood NAD Measurements May Signal Cardiovascular Problems Rather Than Normal Aging
Share
PinterestFacebookLinkedInRedditTelegramX
Nov 21, 2026
Longevity Technology & Future Science

On November 4, 2026, Nature Metabolism published Whole-blood NAD levels track cardiovascular disease but not chronological age. The research involved adults recruited in Lithuania between 2023 and 2025.

The study’s central finding was that whole-blood NAD showed no significant association with age in healthy men and increased modestly with age in healthy women. The researchers estimated an age-associated increase of 0.07 μM per year in healthy women. Lower whole-blood NAD was instead associated with cardiovascular disease, including comparisons involving hypertension. For longevity research, the authors’ conclusion challenges the assumption that healthy adults generally develop a whole-blood NAD deficit as they grow older.

How to read the human evidence

Conducted in humans: an observational study with a cross-sectional main analysis.

The main population analysis included 1,068 adults: 636 women and 432 men. Samples were collected under standardized morning and fasting conditions. Across the study programme, the researchers reported 1,340 measurements.

The authors also described small exploratory components involving supplement users. These addressed a different question from the population analysis. The population comparison examined patterns across participants, while the exploratory observations described measured blood changes during supplement use.

The researchers place their findings within an unsettled field of human blood NAD research. They say the absence of an age-related decline independently replicated earlier work using a different method and population. That context is useful when weighing claims built around blood NAD, rather than judging a result only by how surprising its headline sounds.

Reading the paper therefore requires keeping three questions separate: how the measurement relates to age; how it differs between disease groups; and whether changing it improves health. Those questions concern different outcomes. A persuasive answer to one does not automatically answer the others.

Why the findings need a careful reading

  • A cross-sectional comparison is not an individual aging trajectory. The main analysis sampled participants once rather than following their blood NAD throughout aging. Its age associations describe differences between people of different ages. In particular, the estimated increase in healthy women should not be read as the amount an individual woman’s NAD will rise each year. Treat these slopes as population-level observations rather than forecasts of a person’s future laboratory results.
  • Evidence in the oldest healthy adults was limited. The authors identify limited information about disease-free adults over age 70 as a weakness. That gap matters when interpreting a conclusion about healthy aging across adulthood. The result applies most directly to the participants represented in the study, not automatically to every older population. A claim about NAD in the oldest adults would need stronger representation of that group rather than an assumption that the observed relationship continues unchanged into later life.
  • Disease classification and medication use complicate the cardiovascular comparison. The chronic-disease group included 243 people. For condition-specific comparisons, the researchers retained 197 participants after excluding cases whose reported diagnosis or medication could not be reliably classified. Disease categories were not mutually exclusive, and the authors acknowledge that medication could contribute to observed differences. The study therefore cannot determine whether lower NAD contributes to cardiovascular disease or follows from it, nor whether other influences explain the association.
  • The assay measured total NAD rather than NAD+ alone. The core analysis used dried blood spots and measured NAD+ plus NADH. The authors say total NAD can approximate liquid-blood NAD+ under some conditions, but that assumption may not hold in disease contexts. This distinction matters when a headline or testing claim uses “NAD+” as shorthand for the paper’s measurement. The accurate description is total NAD in dried blood spots, with the sample type and measured substances kept visible.
  • Blood is not a direct readout of solid tissues. In an accompanying commentary, Stephen J. Gardell and Joseph A. Baur emphasize that blood NAD is an incomplete proxy for NAD metabolism throughout the body. They point to metabolic differences between red blood cells and solid tissues. The study’s authors likewise say their findings do not contradict reports of age-related NAD decline in skeletal muscle, brain and skin. The practical distinction is between a finding about whole blood and a claim about NAD across the body.
  • The measurement has an additional blood-cell limitation. According to the authors, whole-blood NAD comes largely from red blood cells. Their dried-blood-spot method does not measure hematocrit, which they identify as a limitation of the approach. This belongs in the interpretation of the assay rather than being treated as an incidental technical detail. When assessing a laboratory claim, readers should look for an explanation of how the sample was measured and which relevant variables were recorded alongside it.
  • An association is not validation of a cardiovascular test. The researchers reported lower whole-blood NAD in cardiovascular-disease groups, with different age-related patterns in men and women with disease. They did not establish diagnostic thresholds or predictive accuracy. Nor did they show that adding NAD measurement improves cardiovascular-risk assessment. Before presenting the assay as clinically useful, research would need to demonstrate what decisions it improves and how its results relate to meaningful outcomes, rather than relying on a difference between groups.
  • Supplement-related laboratory changes were not health outcomes. In two self-directed NMN users, the researchers recorded higher whole-blood NAD during supplementation. The paper also described uncontrolled observations among supplement users in the main cohort. These small exploratory components do not establish clinical benefit or show that supplementation prevents or treats cardiovascular disease or hypertension. The authors conclude that their findings provide no broad rationale for NAD-boosting interventions and call for adequately powered trials and long-term safety data before broader conclusions about efficacy or safety.

How to match a NAD claim to its evidence

The practical response is to identify the exact question a claim is trying to answer. A statement about chronological age should name age as its endpoint. A cardiovascular claim should specify the clinical outcome it aims to inform. A supplement claim should identify the human benefit being tested rather than substituting a change in the measured blood value.

This is also a useful framework for interpreting blood-based aging indicators. Start with the sample and measured substance. Then identify the population and outcome. Finally, ask whether the proposed use matches the evidence actually collected.

Applied here, that approach produces a more precise interpretation than either dismissing NAD biology or promoting NAD testing. The healthy-adult findings challenge an assumed universal blood deficit. The cardiovascular findings identify an association worth investigating. Each result has a distinct research role.

For readers interested in heart health, the appropriate context is evidence for cardiovascular prevention rather than treating an emerging laboratory association as a replacement for established assessment. Personal decisions about testing or supplements belong with a qualified healthcare professional who can consider the individual’s broader health context.

Why the next study needs to follow people over time

The next step is prospective research with repeated measurements to test cardiovascular prediction, alongside adequately powered trials that assess whether NAD-related interventions improve meaningful health outcomes safely.

How AgeAmaze helps

Blood NAD headlines require a choice between reporting a laboratory association and implying a health benefit; AgeAmaze explains the research behind that distinction. Its readable coverage helps skeptical adults assess overstated biological-age and supplement claims by showing how strongly a finding supports an emerging intervention.

Read the research

Sources

  1. Whole-blood NAD levels track cardiovascular disease but not chronological age - Nature Metabolism
  2. The bleeding edge of NAD in human ageing | Nature Metabolism

Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.

FacebookInstagramYouTubeXPinterest

Continue reading

Fasting-Mimicking Diet Research: Biomarkers Before Lifespan Claims
November 21, 2026
Cellular Health & Metabolism

Fasting-Mimicking Diet Research: Biomarkers Before Lifespan Claims

read article
Senolytics vs. Senomorphics: Different Actions, Different Evidence
November 21, 2026
Peptides & Emerging Therapies

Senolytics vs. Senomorphics: Different Actions, Different Evidence

read article
Yale Evidence Summary Puts Healthy Diets Ahead of Popular Supplements on DNA-Aging Measures
November 21, 2026
Nutrition & Supplements

Yale Evidence Summary Puts Healthy Diets Ahead of Popular Supplements on DNA-Aging Measures

read article
keep reading

Longevity research changes faster than the headlines

Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.

read the Blog
Woman reading health research at a table in natural daylight